197 related articles for article (PubMed ID: 29769167)
1. Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial.
Gargiulo G; da Costa BR; Frigoli E; Palmieri C; Nazzaro MS; Falcone C; Liso A; Vigna C; Abate F; Comeglio M; Diletti R; Gabrielli G; Di Lorenzo E; Mazzarotto P; Zimarino M; Moretti C; Colombo A; Penzo C; Pasquetto G; Brugaletta S; Ferrari F; Casu G; Guiducci V; Dellavalle A; Liistro F; Mauro C; Van't Hof AWJ; Omerovic E; Curello S; de la Torre Hernandez JM; De Servi S; Belloni F; Windecker S; Valgimigli M
EuroIntervention; 2019 Jun; 15(3):e269-e278. PubMed ID: 29769167
[TBL] [Abstract][Full Text] [Related]
2. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
[TBL] [Abstract][Full Text] [Related]
3. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.
Valgimigli M; Frigoli E; Leonardi S; Rothenbühler M; Gagnor A; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andò G; Repetto A; Limbruno U; Garbo R; Sganzerla P; Russo F; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Presbitero P; Santarelli A; Sardella G; Varbella F; Tresoldi S; de Cesare N; Rigattieri S; Zingarelli A; Tosi P; van 't Hof A; Boccuzzi G; Omerovic E; Sabaté M; Heg D; Jüni P; Vranckx P;
N Engl J Med; 2015 Sep; 373(11):997-1009. PubMed ID: 26324049
[TBL] [Abstract][Full Text] [Related]
4. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
[TBL] [Abstract][Full Text] [Related]
5. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome.
Gargiulo G; Carrara G; Frigoli E; Leonardi S; Vranckx P; Campo G; Varbella F; Calabrò P; Zaro T; Bartolini D; Briguori C; Andò G; Ferrario M; Limbruno U; Colangelo S; Sganzerla P; Russo F; Nazzaro MS; Esposito G; Ferrante G; Santarelli A; Sardella G; Windecker S; Valgimigli M
J Am Coll Cardiol; 2019 Feb; 73(7):758-774. PubMed ID: 30784669
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
Saad M; Nairooz R; Rashed A; Abdelaziz HK; Mentias A; Abbott JD
Cardiovasc Revasc Med; 2017 Sep; 18(6):418-424. PubMed ID: 28291727
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Meng S; Xu J; Guo L; Huang R
Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
[TBL] [Abstract][Full Text] [Related]
8. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
[TBL] [Abstract][Full Text] [Related]
9. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
10. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions.
Grajek S; Michalak M; Gwizdała A; Araszkiewicz A; Grygier M; Hiczkiewicz J; Lesiak M
Kardiol Pol; 2018; 76(4):740-749. PubMed ID: 29350380
[TBL] [Abstract][Full Text] [Related]
11. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials.
Shah R; Matin K; Rogers KC; Rao SV
Catheter Cardiovasc Interv; 2017 Aug; 90(2):196-204. PubMed ID: 27862911
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C
Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials.
Cassese S; Byrne RA; Laugwitz KL; Schunkert H; Berger PB; Kastrati A
EuroIntervention; 2015 Jun; 11(2):196-203. PubMed ID: 25102830
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention.
Shah R; Jovin IS; Chaudhry A; Haji SA; Askari R; Dennis MM; Berzingi C; Rao SV
Catheter Cardiovasc Interv; 2019 Feb; 93(2):241-247. PubMed ID: 30269393
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
18. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.
Chang CC; Chichareon P; Modolo R; Takahashi K; Kogame N; Tomaniak M; Gao C; Royaards KJ; Cequier A; Oldroyd K; Steg PG; Hamm C; Jüni P; Valgimigli M; Windecker S; Onuma Y; Stables RH; Jan van Geuns R; Serruys PW
Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):22-30. PubMed ID: 31841136
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study.
Mallidi JR; Robinson P; Visintainer PF; Lotfi AS; Mulvey S; Giugliano GR
Catheter Cardiovasc Interv; 2017 Nov; 90(6):898-904. PubMed ID: 28417608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
